Pardes Biosciences

Biotechnology, Life Science
Founded in 1/1/20
Carlsbad, California, United States
http://www.pardesbio.com/
For Profit

About Pardes Biosciences

Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.

Company Metrics

  • Employees: 51-100
  • Monthly Visits: 3982
  • Tech Stack: None active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 126614997 USD
  • Last Funding: 75000000 USD (Post-IPO Equity)
  • Funding Status: IPO

Technology Stack

Pardes Biosciences actively uses None products in their tech stack.

Market Presence

Industries: Biotechnology, Life Science

Headquarters: Carlsbad, California, United States

Employees

  • Brian Kearney - Chief Development Officer (LinkedIn)
  • Heidi Henson - Chief Financial Officer (LinkedIn)
  • Sean Brusky - Chief Commercial Officer // Head of Go-to-Market Innovation (LinkedIn)